Literature DB >> 12404122

Cyclin D1-dependent regulation of B-myb activity in early stages of neuroblastoma differentiation.

V Cesi1, B Tanno, R Vitali, C Mancini, M L Giuffrida, B Calabretta, G Raschellà.   

Abstract

Levels of the transcription factor B-myb must be down-regulated to allow terminal differentiation of neuroectodermal cells and yet its constitutive expression induces early markers of neural differentiation. Thus, we investigated potential mechanisms of enhanced B-myb activity in early stages of neural differentiation. We report here that B-myb expression does not decrease, cyclin A and Sp1 levels remain constant while p21 levels increase continuously upon retinoic acid-induced differentiation of the LAN-5 neuroblastoma cell line. In contrast, cyclin D1 expression is down-regulated at the onset of the differentiative process by protein destabilization. Luciferase assays of promoter activity indicate that B-myb-dependent transactivation is enhanced in LAN-5 cells treated with retinoic acid (RA) for 24 h. The enhancement is independent from cyclin A but is suppressed by a degradation-resistant mutant form of cyclin D1. The importance of cyclin D1 in controlling B-myb activity is further suggested by co-immunoprecipitation experiments, showing that the amount of cyclin D1 co-immunoprecipitated with B-myb decreased after RA treatment. Thus, B-myb may play an active role in the early stages of differentiation when its transactivation activity is enhanced as a consequence of cyclin D1 down-modulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404122     DOI: 10.1038/sj.cdd.4401103

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  8 in total

1.  B-myb is a gene implicated in cell cycle and proliferation of breast cancer.

Authors:  Deyou Tao; Yihong Pan; Hongsheng Lu; Song Zheng; Hui Lin; Hongyan Fang; Feilin Cao
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.

Authors:  Chuanbing Zang; Marlies Wächter; Hongyu Liu; Maximilian G Posch; Martin H Fenner; Christine Stadelmann; Andreas von Deimling; Kurt Possinger; Keith L Black; H Phillip Koeffler; Elena Elstner
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

3.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

4.  BM88/CEND1 coordinates cell cycle exit and differentiation of neuronal precursors.

Authors:  Panagiotis K Politis; Georgia Makri; Dimitra Thomaidou; Markus Geissen; Hermann Rohrer; Rebecca Matsas
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-30       Impact factor: 11.205

5.  Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis.

Authors:  Steffen Blenk; Julia C Engelmann; Stefan Pinkert; Markus Weniger; Jörg Schultz; Andreas Rosenwald; Hans K Müller-Hermelink; Tobias Müller; Thomas Dandekar
Journal:  BMC Cancer       Date:  2008-04-16       Impact factor: 4.430

6.  Functional Interactions between BM88/Cend1, Ran-binding protein M and Dyrk1B kinase affect cyclin D1 levels and cell cycle progression/exit in mouse neuroblastoma cells.

Authors:  Konstantinos Tsioras; Florentia Papastefanaki; Panagiotis K Politis; Rebecca Matsas; Maria Gaitanou
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

7.  PCLAF promotes neuroblastoma G1/S cell cycle progression via the E2F1/PTTG1 axis.

Authors:  Xiaowei Liu; Yuanxia Cai; Cheng Cheng; Yaoyao Gu; Xiaoxiao Hu; Kai Chen; Yeming Wu; Zhixiang Wu
Journal:  Cell Death Dis       Date:  2022-02-24       Impact factor: 8.469

8.  Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomas.

Authors:  Hardeep Kataria; Renu Wadhwa; Sunil C Kaul; Gurcharan Kaur
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.